TESARO Inc (NASDAQ:TSRO) SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at $690,529.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

TESARO Inc (NASDAQ:TSRO) traded down $0.22 on Thursday, reaching $84.76. The company had a trading volume of 588,300 shares, compared to its average volume of 1,019,860. TESARO Inc has a 12-month low of $79.03 and a 12-month high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.

TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. During the same period in the previous year, the company earned ($1.72) EPS. The company’s revenue for the quarter was up 740.3% on a year-over-year basis. equities analysts expect that TESARO Inc will post -8.17 earnings per share for the current year.

A number of brokerages have commented on TSRO. Credit Suisse Group set a $190.00 price objective on TESARO and gave the stock a “buy” rating in a research report on Friday, August 18th. Morgan Stanley restated an “overweight” rating and set a $183.00 price objective on shares of TESARO in a research report on Thursday, August 10th. HC Wainwright restated a “buy” rating and set a $158.00 price objective on shares of TESARO in a research report on Monday, November 20th. Evercore ISI began coverage on TESARO in a research report on Wednesday, August 16th. They set an “in-line” rating and a $121.00 price objective for the company. Finally, SunTrust Banks restated a “buy” rating and set a $160.00 price objective on shares of TESARO in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $159.39.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its position in TESARO by 0.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 90,684 shares of the biopharmaceutical company’s stock worth $13,954,000 after buying an additional 363 shares during the period. Capstone Asset Management Co. bought a new position in TESARO in the 2nd quarter worth approximately $238,000. Bank of Montreal Can increased its position in TESARO by 156.5% in the 2nd quarter. Bank of Montreal Can now owns 5,863 shares of the biopharmaceutical company’s stock worth $820,000 after buying an additional 3,577 shares during the period. Aperio Group LLC increased its position in TESARO by 4.5% in the 2nd quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 156 shares during the period. Finally, Sumitomo Mitsui Asset Management Company LTD bought a new position in TESARO in the 2nd quarter worth approximately $354,000.

TRADEMARK VIOLATION NOTICE: “Martin H. Jr. Huber Sells 829 Shares of TESARO Inc (TSRO) Stock” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://theolympiareport.com/2017/12/07/martin-h-jr-huber-sells-829-shares-of-tesaro-inc-tsro-stock.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.